Prostate cancer overview. Part 2: Metastatic prostate cancer

British Journal of Nursing

Volumn 21, Issue 18 SUPPL., 2012, Pages

  Drudge Coates, Lawrence ^a   Turner, Bruce ^b  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Castrate resistant prostate cancer; Metastatic prostate cancer; Nursing role; Patient support; Skeletal related events

Indexed keywords

HUMAN; MALE; METASTASIS; METHODOLOGY; NURSING; ONCOLOGY NURSING; PROSTATE TUMOR; REVIEW;

HUMANS; MALE; ONCOLOGIC NURSING; PROSTATIC NEOPLASMS;

EID: 84869163844     PISSN: 09660461     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Cancer Research UK (2011) Prostate Cancer Incidence Statistics. Cancer Research UK, London. tinyurl.com/7yd34zo (accessed 2 October 2012)
2. Couper J W, Love AW, Duchesne GM et al (2010) Predictors of psychosocial distress 12 months after diagnosis with early and advanced prostate cancer. Med J Aust 193(5 Suppl): S58-61
3. Cruz Guerra NA (2009) Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument. Arch Esp Urol 62(6): 431-57
4. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747): 1147-54
5. de Bono JS, Logothetis C, Molina A, Fizazi K et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21): 1995-2005
6. Drudge-Coates L, Turner B (2012) Treatment-related osteonecrosis of the jaw: presentation and management. Cancer Nursing Practice 11(5): 28-35
7. Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA (2008) Evidence-based standards for cancer pain management. J Clin Oncol 26(23): 3879-85
8. Eisenberger MA, Walsh PC (1999) Early androgen deprivation for prostate cancer? N Engl J Med 341(24): 1837-8
9. Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768): 813-22
10. Grunfeld E, Halliday A, Martin P, Drudge-Coates L (2012) Andropause syndrome in men treated for metastatic prostate cancer: a qualitative study of the impact of symptoms. Cancer Nurs 35(1): 63-9
11. Harris W P, Mostaghel EA, Nelson PS Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6(2): 76-85
12. Hatoum HT, Lin SJ, Smith MR, Bargout V, Lipton A (2008) Zoledronic acid and skeletal complications in patients with solid tumours and bone metastases: analysis of a national medical claims database. Cancer 113(6): 1438-45
13. Heidenreich A, Bastian PJM, Bellmunt et al (2012) Guidelines on Prostate Cancer. European Association of Urology, Arnhem, the Netherlands. www.uroweb.org/gls/df/08 Prostate Cancer-LR March 13th 2012.pdf (accessed 2 October 2012)
14. Hoskin P (2010) Radiotherapy for bone metastases. In: Coleman RE, Abrahamsson PA, Hadji P, eds, Handbook of Cancer-Related Bone Disease. BioScientifica, Bristol: 163-17
15. Kantoff P W, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5): 411-22
16. Klotz L, Boccon-Gibod L, Shore ND et al (2008). The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102(11): 1531-8
17. Langford DJ, Tripathy D, Paul SM et al (2011) Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. J Pain 12(4): 495-507
18. Medivation (2012) Medivation and Astellas Announce Positive Results from the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients who Received Prior Chemotherapy. Press release. Medivation, San Francisco http://investors.medivation.com/releasedetail.cfm?ReleaseID=644382 (accessed 2 October 2012)
19. Moul JW (2009) Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer 115(15): 3376-8
20. National Institute for Health and Clinical Excellence (2012a) Prostate Cancer-Cabazitaxel. Cabazitaxel for the Second Line Treatment of Hormone Refractory, Metastatic Prostate Cancer. NICE, London. http://guidance.nice.org. uk/TA/Wave23/31 (accessed 2 October 2012)
21. National Institute for Health and Clinical Excellence (2012b) TA259 Prostate cancer (metastatic, castration resistant)-abiraterone (following cytoxic therapy): guidance. NICE, London. http://tinyurl.com/8sewxjw (accessed 4 October 2012)
22. Oh WK, Kantoff P W, Weinberg V et al (2004) Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPE, S and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 22(18): 3705-12 (Pubitemid 41095210)
23. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11): 879-882. (Pubitemid 38807610)
24. Sartor AO, Heinrich D, Helle SI et al (2012) Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: a phase III randomized trial (ALSYMPCA). J Clin Oncol 30(Suppl 5; abstr 9)
25. Sartor AO, Tangen CM, Hussain MH et al (2008) Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112(11): 2393-400
26. Saylor PJ, Smith MR (2010) Bone health and prostate cancer. Prostate Cancer Prostatic Dis 13(1): 20-7
27. Small EJ, Halabi S, Dawson NA et al (2004) Antiandrogen withdrawal alone or in combination with ketokonazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22(6): 1025-33 (Pubitemid 41095034)
28. Tannock I F, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-12 (Pubitemid 39315317)
29. Walsh PC (1975) Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2(1):125-40
30. Wilkinson S, Chodak G (2004) An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. Eur Urol 45(5): 581-4; discussion: 585